Primary Targets of Tigecycline
Tigecycline, a glycylcycline antibiotic, primarily targets multidrug-resistant Acinetobacter baumannii, a gram-negative bacterium notorious for causing ventilator-associated pneumonia, bloodstream infections, and wound infections in hospital settings. It inhibits protein synthesis by binding to the 30S ribosomal subunit, effective against strains resistant to other tetracyclines, carbapenems, and polymyxins.[1]
How Tigecycline Works Against A. baumannii
Tigecycline overcomes efflux pumps and ribosomal protection mechanisms in A. baumannii, achieving low MIC values (often ≤2 μg/mL). Clinical trials like TEST (2004–2007) showed 90–95% susceptibility rates among isolates, though rising resistance via efflux overexpression limits its use today.[2][3]
Other Key Bacterial Strains It Targets
Beyond A. baumannii, tigecycline covers:
- Escherichia coli and Klebsiella pneumoniae (including ESBL-producers).
- Enterobacter cloacae and Pseudomonas aeruginosa (variable activity; less reliable for P. aeruginosa).
- Anaerobes like Bacteroides fragilis and gram-positives such as Staphylococcus aureus (MRSA) and Streptococcus pneumoniae.
FDA approval (2005) emphasized complicated skin/skin structure infections and intra-abdominal infections driven by these pathogens.[1]
Why Focus on Multidrug-Resistant Strains?
Tigecycline fills gaps left by failing beta-lactams in ICU patients. Surveillance data (e.g., SENTRY program) confirm >85% susceptibility in A. baumannii globally, but U.S. rates dipped to 70–80% by 2010s due to tet(X) genes.[3]
Limitations and Resistance Concerns
Does not cover Proteus, Providencia, or P. aeruginosa reliably due to poor activity. FDA warnings highlight higher mortality in ventilator-associated pneumonia (5.5% vs. 3.9% comparators), prompting restricted labeling. Resistance emerges via mutations in ribosomal proteins or efflux (e.g., AdeABC pumps in A. baumannii).[2]
When Is Tigecycline Used for These Strains?
Reserved for polymyxin-intolerant cases; dosing is 100 mg IV load, then 50 mg q12h. No oral form exists.
[1]: FDA Label - Tygacil (tigecycline)
[2]: Clinical Infectious Diseases - Tigecycline Review (2013)
[3]: Antimicrobial Agents and Chemotherapy - Surveillance Data (2010)